RecruitingEarly Phase 1NCT07240896

A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)

Sponsor

DSciLab Co., Ltd.

Enrollment

18 participants

Start Date

Dec 31, 2025

Study Type

INTERVENTIONAL

Conditions

Wilsons Disease

Summary

This study adopted an open, single-arm, non-randomized, dose-escalation research design, aiming to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic and immunogenicity characteristics of single and multiple intravenous infusions of DSL101 in patients with Wilson's disease.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Group 1: DSL101 Low dose, a drug called Group 2: DSL101 Medium dose, and others for people with wilsons disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGroup 1: DSL101 Low dose

Subjects will receive intravenous infusions of DSL101 once every four weeks.

DRUGGroup 2: DSL101 Medium dose

Subjects will receive intravenous infusions of DSL101 once every four weeks.

DRUGGroup 3: DSL101 High dose

Subjects will receive intravenous infusions of DSL101 once every four weeks.

Locations(1)

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07240896